influenza vaccine (Vanderbilt-Ingram Cancer Center)

This designation refers to a clinical research program conducted by the Vanderbilt-Ingram Cancer Center evaluating optimized influenza vaccination strategies in hematopoietic stem cell transplant (HSCT) recipients. The associated trials (NCT03179761 for adults and NCT02860039 for pediatrics) compare the immunogenicity and safety of high-dose trivalent inactivated influenza vaccine (HD-TIV) against standard-dose quadrivalent inactivated influenza vaccine (SD-QIV). These vaccines are biologics composed of inactivated influenza virus antigens that target the hemagglutinin proteins of influenza A and B viruses. The research aims to determine if a high-dose formulation or a two-dose schedule can provide superior protection for highly immunocompromised patients who are at significantly increased risk for severe influenza-related morbidity and mortality.

Other names

High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant RecipientsHD-TIVSD-QIVHigh-dose trivalent inactivated influenza vaccineStandard-dose quadrivalent inactivated influenza vaccine